Matches in SemOpenAlex for { <https://semopenalex.org/work/W2075319611> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2075319611 endingPage "A277" @default.
- W2075319611 startingPage "A277" @default.
- W2075319611 abstract "In a real-world setting, adherence to antiviral therapies is often subpar and treatment outcomes are consequently compromised. This study evaluated the adherence rate to HCV therapy in a Medicaid population. Patients eligible for this study were Texas Medicaid patients ≥18 years who had evidence of chronic HCV during the identification period (1/1/07 – 9/30/11) and were continuously enrolled throughout the assessment period. Primary outcome was adherence to pegylated interferon (Peg-IFN) and telaprevir (TLV) or boceprevir (BOC) as measured by proportion of days covered (PDC) using refill history. Univariate and multivariate logistic regression analysis evaluated predictors for adherence, such as age (<55, ≥55), gender, Charlson comorbidity index (CCI), race (Whites vs. Non-Whites), presence of medical/psychosocial comorbidities, number of prescription drugs and office visits (intervals of 10), and evidence of adherence to other chronic medications (coronary artery disease and diabetes). A total of 24,032 patients were identified as having chronic HCV; 9.4% with evidence of receiving HCV treatment. Of those treated, 11.2% were initiated on therapy with either TLV or BOC in 2011. The average HCV medication PDC was 70% with a significant difference between the first 12 weeks and the following 12 weeks of therapy (79% vs. 60%, p<0.001). Significant positive independent predictors of HCV medication PDC greater than 70% included male gender (OR: 1.42, 95% CI: 1.08-1.86), higher number of non-HCV prescription drugs (OR: 1.11, 95% CI: 1.02-1.21) and higher number of outpatient visits (OR: 1.19, 95% CI: 1.08-1.31). Age, CCI, race and adherence levels to other chronic medications were not significant independent predictors for HCV medication PDC. Overall adherence for HCV therapy was poor (70%), especially after the initial 12 weeks of therapy (60%). Closer follow-up and management of other comorbidities may improve readiness to HCV therapy and improve treatment adherence." @default.
- W2075319611 created "2016-06-24" @default.
- W2075319611 creator A5019684939 @default.
- W2075319611 creator A5026604545 @default.
- W2075319611 creator A5036046947 @default.
- W2075319611 creator A5042091558 @default.
- W2075319611 creator A5088711516 @default.
- W2075319611 date "2014-05-01" @default.
- W2075319611 modified "2023-10-16" @default.
- W2075319611 title "Poor Adherence To Hcv Medication In A Medicaid Population" @default.
- W2075319611 doi "https://doi.org/10.1016/j.jval.2014.03.1614" @default.
- W2075319611 hasPublicationYear "2014" @default.
- W2075319611 type Work @default.
- W2075319611 sameAs 2075319611 @default.
- W2075319611 citedByCount "0" @default.
- W2075319611 crossrefType "journal-article" @default.
- W2075319611 hasAuthorship W2075319611A5019684939 @default.
- W2075319611 hasAuthorship W2075319611A5026604545 @default.
- W2075319611 hasAuthorship W2075319611A5036046947 @default.
- W2075319611 hasAuthorship W2075319611A5042091558 @default.
- W2075319611 hasAuthorship W2075319611A5088711516 @default.
- W2075319611 hasBestOaLocation W20753196111 @default.
- W2075319611 hasConcept C126322002 @default.
- W2075319611 hasConcept C160735492 @default.
- W2075319611 hasConcept C162324750 @default.
- W2075319611 hasConcept C203014093 @default.
- W2075319611 hasConcept C2426938 @default.
- W2075319611 hasConcept C2522874641 @default.
- W2075319611 hasConcept C2776408679 @default.
- W2075319611 hasConcept C2776534028 @default.
- W2075319611 hasConcept C2777159539 @default.
- W2075319611 hasConcept C2778159067 @default.
- W2075319611 hasConcept C2779159551 @default.
- W2075319611 hasConcept C2780040827 @default.
- W2075319611 hasConcept C2908647359 @default.
- W2075319611 hasConcept C50522688 @default.
- W2075319611 hasConcept C71924100 @default.
- W2075319611 hasConcept C98274493 @default.
- W2075319611 hasConcept C99454951 @default.
- W2075319611 hasConceptScore W2075319611C126322002 @default.
- W2075319611 hasConceptScore W2075319611C160735492 @default.
- W2075319611 hasConceptScore W2075319611C162324750 @default.
- W2075319611 hasConceptScore W2075319611C203014093 @default.
- W2075319611 hasConceptScore W2075319611C2426938 @default.
- W2075319611 hasConceptScore W2075319611C2522874641 @default.
- W2075319611 hasConceptScore W2075319611C2776408679 @default.
- W2075319611 hasConceptScore W2075319611C2776534028 @default.
- W2075319611 hasConceptScore W2075319611C2777159539 @default.
- W2075319611 hasConceptScore W2075319611C2778159067 @default.
- W2075319611 hasConceptScore W2075319611C2779159551 @default.
- W2075319611 hasConceptScore W2075319611C2780040827 @default.
- W2075319611 hasConceptScore W2075319611C2908647359 @default.
- W2075319611 hasConceptScore W2075319611C50522688 @default.
- W2075319611 hasConceptScore W2075319611C71924100 @default.
- W2075319611 hasConceptScore W2075319611C98274493 @default.
- W2075319611 hasConceptScore W2075319611C99454951 @default.
- W2075319611 hasIssue "3" @default.
- W2075319611 hasLocation W20753196111 @default.
- W2075319611 hasOpenAccess W2075319611 @default.
- W2075319611 hasPrimaryLocation W20753196111 @default.
- W2075319611 hasRelatedWork W1542338870 @default.
- W2075319611 hasRelatedWork W1995824818 @default.
- W2075319611 hasRelatedWork W2039584666 @default.
- W2075319611 hasRelatedWork W2066195614 @default.
- W2075319611 hasRelatedWork W2094190427 @default.
- W2075319611 hasRelatedWork W2150000634 @default.
- W2075319611 hasRelatedWork W2169503918 @default.
- W2075319611 hasRelatedWork W2316541736 @default.
- W2075319611 hasRelatedWork W2375774240 @default.
- W2075319611 hasRelatedWork W2599978308 @default.
- W2075319611 hasVolume "17" @default.
- W2075319611 isParatext "false" @default.
- W2075319611 isRetracted "false" @default.
- W2075319611 magId "2075319611" @default.
- W2075319611 workType "article" @default.